Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia.

Buchanan RW, Freedman R, Javitt DC, Abi-Dargham A, Lieberman JA.

Schizophr Bull. 2007 Sep;33(5):1120-30. Epub 2007 Jul 19. Review.

2.

The neurobiology of cognition in schizophrenia.

Tamminga CA.

J Clin Psychiatry. 2006;67 Suppl 9:9-13; discussion 36-42. Review.

3.

The neurobiology of cognition in schizophrenia.

Tamminga CA.

J Clin Psychiatry. 2006 Sep;67(9):e11. Review.

4.

Molecular targets for treating cognitive dysfunction in schizophrenia.

Gray JA, Roth BL.

Schizophr Bull. 2007 Sep;33(5):1100-19. Epub 2007 Jul 7. Review.

5.

The effects of clozapine on neurocognition: an overview.

Goldberg TE, Weinberger DR.

J Clin Psychiatry. 1994 Sep;55 Suppl B:88-90. Review.

PMID:
7525543
6.

New paradigms for treatment development.

Stover EL, Brady L, Marder SR.

Schizophr Bull. 2007 Sep;33(5):1093-9. Epub 2007 Aug 2.

7.

Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists.

Radek RJ, Kohlhaas KL, Rueter LE, Mohler EG.

Curr Pharm Des. 2010 Jan;16(3):309-22. Review.

PMID:
20109141
8.

Wayne Fenton's impact on academic neuroscience.

Geyer MA, Tamminga CA.

Schizophr Bull. 2007 Sep;33(5):1156-9. Epub 2007 Jul 7.

9.

The role of the α7 nicotinic receptor in cognitive processing of persons with schizophrenia.

AhnAllen CG.

Curr Opin Psychiatry. 2012 Mar;25(2):103-8. doi: 10.1097/YCO.0b013e3283503637. Review.

PMID:
22262029
10.

Drug targets for cognitive enhancement in neuropsychiatric disorders.

Wallace TL, Ballard TM, Pouzet B, Riedel WJ, Wettstein JG.

Pharmacol Biochem Behav. 2011 Aug;99(2):130-45. doi: 10.1016/j.pbb.2011.03.022. Epub 2011 Apr 1. Review.

PMID:
21463652
11.
12.

Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia.

Koola MM, Buchanan RW, Pillai A, Aitchison KJ, Weinberger DR, Aaronson ST, Dickerson FB.

Schizophr Res. 2014 Aug;157(1-3):84-9. doi: 10.1016/j.schres.2014.04.037. Epub 2014 May 28. Review.

13.

The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.

Goff DC, Coyle JT.

Am J Psychiatry. 2001 Sep;158(9):1367-77. Review.

PMID:
11532718
14.

Executive functioning component mechanisms and schizophrenia.

Kerns JG, Nuechterlein KH, Braver TS, Barch DM.

Biol Psychiatry. 2008 Jul 1;64(1):26-33. doi: 10.1016/j.biopsych.2008.04.027.

PMID:
18549874
15.

Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.

Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE, Stevens JO, Martin L, Adler LE, Soti F, Kem WR, Freedman R.

Arch Gen Psychiatry. 2006 Jun;63(6):630-8.

PMID:
16754836
16.

Treating schizophrenia: novel targets for the cholinergic system.

Money TT, Scarr E, Udawela M, Gibbons AS, Jeon WJ, Seo MS, Dean B.

CNS Neurol Disord Drug Targets. 2010 Apr;9(2):241-56. Review.

PMID:
20053170
17.

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.

Keefe RS, Silva SG, Perkins DO, Lieberman JA.

Schizophr Bull. 1999;25(2):201-22.

PMID:
10416727
18.

Drug initiatives to improve cognitive function.

Marder SR.

J Clin Psychiatry. 2006;67 Suppl 9:31-5; discussion 36-42.

19.

Important steps in the development of cognitive-enhancing drugs in schizophrenia.

Buchanan RW.

Am J Psychiatry. 2006 Nov;163(11):1867-9. No abstract available.

PMID:
17074932
20.

Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review.

Saavedra-Velez C, Yusim A, Anbarasan D, Lindenmayer JP.

J Clin Psychiatry. 2009 Jan;70(1):104-12. Epub 2008 Nov 18. Review.

PMID:
19026265

Supplemental Content

Support Center